Ekuqaleni kukaMatshi, iNational Medical Products Administration yavuma iJaypirca® (pirtobrutinib) ukuba inyangwe abantu abadala abane-chronic lymphocytic leukemia (CLL) okanye i-small lymphocytic lymphoma (SLL) abaye bafumana ubuncinane unyango olunye lwangaphambili, kuquka ne-Bruton's tyrosine kinase (BTK) inhibitor.
I-Pirtobrutinib sisithinteli se-kinase esikhetha kakhulu esisebenzisa indlela entsha yokubopha i-non-covalent ukwandisa inzuzo yokujolisa indlela ye-BTK kwizigulane ze-CLL/SLL ezazinyangwe ngaphambili nge-covalent BTK inhibitor (ibrutinib, acalabrutinib, okanye zanubrutinib). I-Pirtobrutinib yamkelwe yi-US FDA ngoJanuwari 2023 njenge-non-covalent (reversible) BTK inhibitor. Ngo-Okthobha 2024, i-pirtobrutinib yavunywa eTshayina njenge-monotherapy yonyango lwezigulane zabantu abadala abane-relapse okanye refractory mantle cell lymphoma (MCL) abaye bafumana ubuncinane unyango lwe-systemic olubini ngaphambili, kuquka i-Bruton's tyrosine kinase (BTK) inhibitor.
Ukuvunywa kwale ngcaciso intsha kusekelwe kwiziphumo ezivela kuphando lwamazwe ngamazwe, oluneziko ezininzi, olungenamkhethe, lweSigaba sesi-3 se-BRUIN CLL 321. I-BRUIN CLL 321 luvavanyo lokuqala lweSigaba sesi-3 olungenamkhethe ehlabathini olwenziwe kwizigulana ezine-CLL/SLL ezazikhe zanyangwa nge-covalent BTK inhibitor (cBTKi). Olu phononongo lubhalise izigulana ezingama-238 kwaye luvavanye ukusebenza kakuhle kunye nokhuseleko lwe-pirtobrutinib monotherapy ngokuchasene nokukhetha komphandi i-IdelaR (idelalisib kunye ne-rituximab) okanye i-BR (bendamustine kunye ne-rituximab). Iziphumo zibonise ukuba i-pirtobrutinib yandisa kakhulu i-median progression free survival (PFS) xa ithelekiswa nerejimeni yokukhetha komphandi (iinyanga ezili-14.0 vs iinyanga ezi-8.7; umlinganiselo wengozi [HR] = 0.54). Ukongeza, izinga lokuyeka ngenxa yeziganeko ezimbi ezinxulumene nonyango laliphantsi nge-pirtobrutinib (5.2% vs 21.1%), nto leyo exhasa ngakumbi ukusebenza kwayo kunye neengenelo zokunyamezeleka kwizigulana ezazinyangwe ngaphambili nge-covalent BTK inhibitor.
Qhagamshelana Nathi ukuze Uqalise Uhambo Lwakho Lwethemba
ISebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region lizinikele ekuboneleleni izigulane zehlabathi ngokufikelela kunyango lomhlaza oluphambili. Ukuba wena okanye ilungu losapho lijongene nokuxilongwa komhlaza kwaye alizange lifumane mpendulo ingako kunyango oluqhelekileyo, iqela lethu leeNkonzo zeZigulane zeHlabathi likulungele ukukunika ulwazi oluneenkcukacha kunye nezicwangciso zonyango ezenzelwe wena.
Nceda unxibelelane nathi ngale mijelo ilandelayo ukuze ufunde okungakumbi malunga neendlela zonyango lomhlaza:
- Ifowuni: 400-880-3716
- WeChat: 17801183037
- Email: 100085_010@163.com or myimmnet@163.com (Emails are welcome, and we will respond promptly)
ISebe leHlabathi leSibhedlele se-Oncology saseBeijing South Region lijonge phambili ekusebenzisaneni nani ekulweni nomhlaza. Nokuba uphi na emhlabeni, sizimisele ukuninika inkxaso yezonyango egqwesileyo kunye nonyango olunobubele.
Take the first step towards overcoming your illness. Call us at 400-880-3716 or contact us via WeChat at 17801183037 today. You can also email us at 100085_010@163.com or myimmnet@163.com to schedule a one-on-one consultation with our team of experts.
Ixesha leposi: Matshi-12-2026